Steven A Maxwell

US Patent:

20170071905, Mar 16, 2017

Filed:

Nov 28, 2016

Appl. No.:

15/362272

Inventors:

- College Station TX, US
Niam Zhou - College Station TX, US
Dwight Baker - College Station TX, US
Steven A. Maxwell - College Station TX, US
Deeann Wallis - College Station TX, US

International Classification:

A61K 31/395
A61K 45/06

Abstract:

The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.

US Patent:

20160038460, Feb 11, 2016

Filed:

Aug 24, 2015

Appl. No.:

14/834160

Inventors:

- College Station TX, US
Niam Zhou - College Station TX, US
Dwight Baker - College Station TX, US
Steven A. Maxwell - College Station TX, US
Deeann Wallis - College Station TX, US

International Classification:

A61K 31/395
A61K 45/06

Abstract:

The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.

US Patent:

20150017673, Jan 15, 2015

Filed:

Aug 29, 2013

Appl. No.:

14/013842

Inventors:

James Sacchettini - College Station TX, US
Nian Zhou - College Station TX, US
Dwight Baker - College Station TX, US
Steven A. Maxwell - College Station TX, US
Deeann Wallis - College Station TX, US

International Classification:

G01N 33/84
G01N 33/58
A61K 31/435

US Classification:

435 29, 546 17

Abstract:

The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.

US Patent:

20140314878, Oct 23, 2014

Filed:

Jul 2, 2014

Appl. No.:

14/322727

Inventors:

James Sacchettini - College Station TX, US
Niam Zhou - College Station TX, US
Dwight Baker - College Station TX, US
Steven A. Maxwell - College Station TX, US
Deeann Wallis - College Station TX, US

International Classification:

C07D 498/22
A61K 31/675
A61K 31/704
A61K 31/475
A61K 31/573
A61K 31/69
A61K 33/24
A61K 31/7068
A61K 31/136
A61K 31/122
A61K 38/08
A61K 31/4745
A61K 31/337
A61K 31/5377
A61K 31/435

US Classification:

424649, 540453, 514278, 514110, 514 34, 514171, 514 64, 514 49, 514 193, 5142328, 435375

Abstract:

The disclosure provides rifamycin and rifamycin derivative compositions, including rifabutin and rifabutin derivative compositions able to cause drug-sensitization in a cancer cell or inhibition of a cancer cell. The disclosure also provides methods of administering such compositions to cancer cells to sensitize them to drugs, such as chemotherapeutics, or directly inhibit them. The disclosure also provides methods of administering such compositions to increase reactive oxygen species (ROS), particularly superoxides, in cancer cells. The disclosure further provides methods of determining whether a cancer will respond to chemotherapeutics and whether to administer rifamycin or a rifamycin derivative based on ROS levels in cancer cells of a patient.